Blinatumomab: enlisting serial killer T-cells in the war against hematologic malignancies.

ABSTRACT:

Introduction

The approval of blinatumomab signals the long awaited arrival of immunotherapy for acute lymphoblastic leukemia (ALL). Previous options for relapsed or refractory disease were restricted to cytotoxic chemotherapy with limited efficacy and significant toxicity. Through an innovative mechanism of action, blinatumomab stimulates a polyclonal antitumor T-cell response, yielding unprecedented single agent efficacy in the relapsed/refractory setting. Success comes at the cost of immunological toxicities rarely encountered with previous therapies and challenging administration logistics requiring clinical expertise.

Areas covered

All published clinical and preclinical studies using blinatumomab were reviewed in addition to all registered ongoing clinical trials and dat

SUBMITTER: Rogala B 

PROVIDER: S-EPMC4994468 | biostudies-literature | 2015 Jun

REPOSITORIES: biostudies-literature